Jaguar Animal Health, Inc. (NASDAQ:JAGX) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Jaguar Animal Health, Inc. (NASDAQ:JAGX) lost -10.88 Percent and closed its previous trading session at $0.12. The stock traded with the average Volume of 2.54 Million at the end of last session.
Jaguar Animal Health, Inc. (NASDAQ:JAGX) has the Market Capitalization of 13.13 Million. The Stock has its 52-week High of $1.530 and 52-Week Low of $0.100 and it touched its 52-week high on 12/12/16 and 52-Week Low on 11/08/17.
The company reported its last earnings Actual EPS of $-0.06/share. While, the analyst predicted that the company could provide an EPS of $-0.13/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.07/share which shows an Earnings Surprise of 53.8 Percent.
Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Jaguar Animal Health, Inc. (NASDAQ:JAGX) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -29.72% where SMA50 and SMA200 are -39.37% and -79.18% respectively.
The company shows its Return on Assets (ROA) value of -360.1%. The Return on Equity (ROE) value stands at 407.4%. While it’s Return on Investment (ROI) value is -978.1%.
Jaguar Animal Health, Inc. (NASDAQ:JAGX) currently has a Weekly Volatility of 13.45% percent while its Monthly Volatility is at 16.75% percent. While talking about Performance of the Stock, Jaguar Animal Health, Inc. currently has a Weekly performance of -24.72%, monthly performance percentage is -29.41 percent, Quarterly performance is -72.45 percent, 6 months performance shows a percent value of -80.77% and Yearly Performance is -81.66 percent.
Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its product pipeline consists of Mytesi(R), Canalevia(TM), Equilevia(TM) and Neonorm (TM). Jaguar Health Inc., formerly known as Jaguar Animal Health Inc., is based in San Francisco, United States.